Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
OABI 
OmniAb Inc. (OABI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/02/2026: OABI (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $7.33
1 Year Target Price $7.33
| 6 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -41.74% | Avg. Invested days 22 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/02/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 270.64M USD | Price to earnings Ratio - | 1Y Target Price 7.33 |
Price to earnings Ratio - | 1Y Target Price 7.33 | ||
Volume (30-day avg) 8 | Beta 0.86 | 52 Weeks Range 1.22 - 4.02 | Updated Date 01/3/2026 |
52 Weeks Range 1.22 - 4.02 | Updated Date 01/3/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.59 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -810.18% |
Management Effectiveness
Return on Assets (TTM) -12.69% | Return on Equity (TTM) -22.37% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 232205152 | Price to Sales(TTM) 12.83 |
Enterprise Value 232205152 | Price to Sales(TTM) 12.83 | ||
Enterprise Value to Revenue 11.01 | Enterprise Value to EBITDA -10.62 | Shares Outstanding 143955400 | Shares Floating 96545129 |
Shares Outstanding 143955400 | Shares Floating 96545129 | ||
Percent Insiders 12.75 | Percent Institutions 55.87 |
Upturn AI SWOT
OmniAb Inc.
Company Overview
History and Background
OmniAb Inc. was founded in 2017, emerging from the pioneering work in antibody discovery at Ligand Pharmaceuticals. Its core mission is to accelerate the development of novel biologics by providing a proprietary antibody discovery platform. Significant milestones include the successful spin-off from Ligand Pharmaceuticals in 2021 and its subsequent IPO in 2022, enabling further investment in its technology and expansion of its partnerships.
Core Business Areas
- Antibody Discovery Platform: OmniAb's proprietary OmniRatu00ae and OmniMouseu00ae platforms are central to its business. These platforms utilize advanced transgenic animal models and sophisticated screening technologies to generate high-quality antibodies with desirable characteristics, such as specificity, affinity, and developability, for therapeutic applications.
- Partnerships and Collaborations: The company collaborates with pharmaceutical and biotechnology companies, providing access to its antibody discovery platform and expertise. These partnerships often involve upfront payments, milestone payments, and royalties on successfully developed therapeutics.
Leadership and Structure
OmniAb Inc. is led by a management team with extensive experience in biotechnology and drug development. The organizational structure is designed to support its research and development efforts, as well as its partnership and business development activities. Specific leadership roles include CEO, CSO, and CFO, supported by various scientific and operational departments.
Top Products and Market Share
Key Offerings
- OmniRatu00ae and OmniMouseu00ae Platforms: These are proprietary transgenic rodent platforms designed for rapid and efficient generation of high-affinity, highly specific antibodies. The market for antibody discovery platforms is competitive, with key competitors including Absci Corporation (ABSI), Xencor, Inc. (XNCR), and various contract research organizations (CROs) offering similar antibody discovery services. OmniAb's unique selling proposition lies in the breadth and depth of its antibody repertoire generated from these platforms.
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly the biologics sector, is experiencing robust growth driven by the increasing demand for targeted therapies and advancements in biotechnology. The antibody-discovery market is a critical component of this ecosystem, supporting the development of new drugs for a wide range of diseases.
Positioning
OmniAb Inc. is positioned as a leading provider of antibody discovery solutions, differentiated by its proprietary transgenic animal platforms that generate a diverse and high-quality antibody repertoire. Its key competitive advantage lies in its ability to accelerate the drug discovery process for its partners by delivering novel antibody candidates.
Total Addressable Market (TAM)
The global antibody discovery market is substantial and growing. While specific TAM figures for antibody discovery platforms can vary, it is estimated to be in the tens of billions of dollars. OmniAb is positioned to capture a significant share of this market by offering a differentiated and efficient discovery engine that reduces timelines and increases the probability of success for its partners in developing therapeutics.
Upturn SWOT Analysis
Strengths
- Proprietary transgenic antibody discovery platforms (OmniRatu00ae, OmniMouseu00ae)
- Experienced management team with a strong scientific and commercial background
- Established partnerships with pharmaceutical and biotech companies
- Ability to generate a diverse and high-quality antibody repertoire
- Focus on accelerating the development of novel biologics
Weaknesses
- Reliance on partnerships for revenue generation
- As a relatively newer company, it may have less established brand recognition compared to larger players
- Competition from established CROs and other antibody discovery platform providers
- The success of its platform is indirectly tied to the success of its partners' drug development programs
Opportunities
- Expanding its partnership base across various therapeutic areas
- Leveraging its platform for the discovery of antibodies for emerging therapeutic modalities
- Potential for in-house drug development based on its own discoveries
- Growth in the global biologics market
- Advancements in AI and machine learning to enhance antibody discovery
Threats
- Intense competition in the antibody discovery space
- Changes in regulatory landscapes for drug development
- Economic downturns impacting R&D budgets of partner companies
- Emergence of alternative antibody discovery technologies
- Failure of partner drug development programs
Competitors and Market Share
Key Competitors
- Absci Corporation (ABSI)
- Xencor, Inc. (XNCR)
- Thermo Fisher Scientific Inc. (TMO)
- Merck KGaA (MRK.DE)
Competitive Landscape
OmniAb's competitive advantages lie in its unique transgenic platforms that provide a distinct antibody repertoire. However, it faces competition from larger, more established companies with broader service offerings and from specialized CROs. Its ability to secure and maintain strong partnerships will be crucial for sustained success.
Growth Trajectory and Initiatives
Historical Growth: OmniAb Inc.'s historical growth is characterized by its rapid development from a spin-off to a publicly traded company, driven by strategic partnerships and advancements in its discovery platforms. Revenue growth is expected to be closely tied to the success and expansion of its collaborations.
Future Projections: Future growth projections for OmniAb are likely based on analyst estimates that consider the pipeline of drugs being developed by its partners, the expansion of new collaborations, and the potential for further platform enhancements. Successful clinical trial outcomes for partnered drugs would be a significant positive driver.
Recent Initiatives: Recent initiatives likely focus on expanding its partnership pipeline, enhancing its discovery platforms through technological advancements, and potentially exploring new therapeutic modalities. Strengthening its intellectual property portfolio and attracting top scientific talent are also key ongoing initiatives.
Summary
OmniAb Inc. possesses a strong foundation with its innovative antibody discovery platforms, positioning it well within the growing biologics market. Its strategic partnerships are a key driver of revenue and growth. However, the company faces significant competition and relies heavily on the success of its partners' drug development programs. Continued investment in platform innovation and expansion of its collaborative network are crucial for long-term success, while managing the inherent risks of drug development.
Similar Stocks
Sources and Disclaimers
Data Sources:
- OmniAb Inc. Investor Relations
- SEC Filings (10-K, 10-Q)
- Industry Research Reports
- Financial News Outlets
Disclaimers:
This information is for informational purposes only and does not constitute financial advice. Stock market data and company performance are subject to change. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About OmniAb Inc.
Exchange NASDAQ | Headquaters EmeryVille, CA, United States | ||
IPO Launch date 2022-11-02 | President, CEO & Director Mr. Matthew W. Foehr | ||
Sector Healthcare | Industry Biotechnology | Full time employees 114 | Website https://www.omniab.com |
Full time employees 114 | Website https://www.omniab.com | ||
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts. Its OmniAb platform's Biological Intelligence powers the immune systems of its proprietary and engineered transgenic animals to create optimized antibody candidates for human therapeutics. The company's animal-based technologies include OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences; OmniFlic, a bispecific rat and OmniClic, a bispecific chicken are designed for discovery of bispecific antibody applications; OmniTaur, which provides cow-inspired antibodies with unique structural characteristics for challenging targets; OmnidAb, an in vivo platform for the discovery of single-domain antibodies based upon a human VH scaffold; and OmniDeep, a suite of in silico, an artificial intelligence (AI) and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. The company has an agreement with mAbsolve Ltd. for its Fc-silencing platform technology to incorporate the STR technology into antibodies that have been generated using OmniAb's antibody discovery platform. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.